IDEAYA Biosciences (NASDAQ:IDYA) Now Covered by Analysts at TD Cowen

Equities research analysts at TD Cowen began coverage on shares of IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) in a report released on Tuesday, MarketBeat reports. The firm set a "buy" rating on the stock.

Other research analysts also recently issued research reports about the company. The Goldman Sachs Group raised IDEAYA Biosciences to a "hold" rating and set a $25.00 price target for the company in a research note on Thursday, July 10th. Royal Bank Of Canada raised IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and cut their price target for the stock from $57.00 to $30.00 in a report on Wednesday, July 9th. JPMorgan Chase & Co. boosted their price target on IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an "overweight" rating in a report on Thursday, May 22nd. Finally, Wells Fargo & Company initiated coverage on shares of IDEAYA Biosciences in a research note on Thursday, June 26th. They issued an "overweight" rating and a $44.00 target price for the company. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $47.55.

IDEAYA Biosciences Trading Up 6.3%

Shares of NASDAQ:IDYA traded up $1.50 during midday trading on Tuesday, hitting $25.13. 1,544,488 shares of the stock were exchanged, compared to its average volume of 1,152,003. The stock has a market cap of $2.20 billion, a P/E ratio of -7.01 and a beta of 0.03. IDEAYA Biosciences has a twelve month low of $13.45 and a twelve month high of $44.42. The company has a 50 day moving average price of $21.20 and a 200-day moving average price of $20.33.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period last year, the business earned ($0.53) earnings per share. On average, equities research analysts expect that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. FMR LLC raised its holdings in IDEAYA Biosciences by 2.6% in the fourth quarter. FMR LLC now owns 12,963,151 shares of the company's stock valued at $333,153,000 after buying an additional 327,498 shares during the period. Janus Henderson Group PLC raised its stake in shares of IDEAYA Biosciences by 13.5% during the fourth quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock valued at $150,606,000 after purchasing an additional 695,263 shares during the period. Vanguard Group Inc. lifted its stake in shares of IDEAYA Biosciences by 0.3% in the first quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company's stock worth $83,417,000 after acquiring an additional 14,535 shares in the last quarter. Deerfield Management Company L.P. Series C increased its stake in shares of IDEAYA Biosciences by 5.5% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock worth $70,315,000 after buying an additional 142,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of IDEAYA Biosciences by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock worth $51,121,000 after buying an additional 43,226 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.